Aduro’s pancreatic cancer immunotherapy fails Phase II trials; shares plunge
May 17, 2016Manufacturing and Production, Research and Development, Sales and Marketing Aduro Biotech, Pancreatic cancer, Stock, drug trial, markets
Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its …
Pfizer to acquire Anacor in $5.2 billion deal
May 16, 2016Manufacturing and Production, Sales and Marketing 5.2 billion, FDA, Pfizer, acquisition, anacor, crisaborole, merger
Pfizer (NYSE: PFE) has acquired Anacor Pharmaceuticals (NASDAQ: ANAC) in a deal worth around $5.2 billion, or $99.25 per share. …
Mylan to buy Renaissance’s dermatology business for up to $1 billion
May 16, 2016Research and Development, Sales and Marketing Mylan, generics, merger and acquisition
Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …
Sanofi to replace entire Medivation board to drive sale, according to reports
May 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Medivation, Sanofi, replace board, takeover
Reports have emerged that Sanofi is looking to step up its efforts to take over oncology firm, Medivation, as it …
Weekly Movers: Teva, Midatech, Allergan…
May 16, 2016Research and Development, Sales and Marketing Allergan, Ariad Pharmaceuticals, Lundbeck, Midatech Pharma, Stock, Teva Pharmaceutical, markets
We have hit the tail end of the earnings season and the near last batch of movers follow result pronouncements …
Novartis says trials show its COPD drug more effective versus GSK’s Seretide
May 16, 2016Research and Development, Sales and Marketing GSK, Novartis, drug trial, research
Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …
Eisai granted additional indication for Lenvima in renal cell carcinoma
May 16, 2016Sales and Marketing Eisai, additional indication, renal cell carcinoma
Eisai has announced that it has received approval from the US Food and Drug Administration (FDA) for an additional indication …
Pfizer presents positive results in meningococcal disease late-stage trials
May 13, 2016Research and Development Pfizer, Vaccine, late stage trials, meningococcal disease
Pfizer (NYSE: PFE) has announced results from two pivotal late-stage trials demonstrating the immunogenicity of Trumenba against invasive meningococcal B …
Clinical Trials Equipment Supplier Woodley Equipment Exhibiting at Outsourcing in Clinical Trials East Coast 2016
May 13, 2016Woodley Equipment Company Limited is exhibiting at Outsourcing in Clinical Trials East Coast 2016. The event is taking place on …
Woodley Equipment Company Limited UK Office
May 13, 2016Woodley Equipment Company Limited UK Office
US pass new laws to combat opioid epidemic
May 13, 2016Medical Communications, Sales and Marketing US, epidemic, fight back, new laws, opioids, reverse
The US has passed new laws that will seek to combat the current epidemic of opioids across the country. The …
EU approves Idelvion for haemophilia B treatment
May 13, 2016Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B
The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …
Sanofi Files Hart-Scott-Rodino notification for Medivation acquisition
May 13, 2016Medical Communications, Sales and Marketing M&A, MA, Medivation, Sanofi, deal
French drugmaker Sanofi (Euronext: SAN) on Friday said it has filed a premerger notification with the US Department of Justice Antitrust …
Sobi, Biogen’s haemophilia B therapy gets European approval
May 13, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi
Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
Bayer terminates clinical trial for hypertension due to safety concerns
May 13, 2016Medical Communications, Research and Development Bayer, clinical trial, deaths, pulmonary hypertension, riociguat, safety concerns
Bayer has terminated a Phase II trial evaluating riociguat in patients with pulmonary hypertension due to fears raised by an …
Takeda appoints new chief financial officer
May 12, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, cfo, james kehoe
Takeda Pharmaceuticals has named James Kehoe its new chief financial officer. He will begin the role on June 15 2016, …
Almost 9 in 10 CCGs not implementing NICE guidelines on antibiotic resistance
May 12, 2016Research and Development, Sales and Marketing CCGs, NICE, antibiotic resistance, failure
The Patients Association has called on all Clinical Commissioning Groups (CCGs) to implement the National Institute for Health and Care …
BMS says Nice refuses backing for its immunotherapy Opdivo to treat lung cancer
May 12, 2016Medical Communications, Research and Development, Sales and Marketing
The National Institute for Health and Care Excellence (Nice) has rejected US pharma firm Bristol-Myers Squibb’s (NYSE: BMY) immune-oncology drug …
Multiple myeloma treatment from BMS and AbbVie scores EU approval
May 12, 2016Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma
Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
FDA issues warning about rare, but serious, side effect in Lilly antipsychotic drug
May 12, 2016Medical Communications, Sales and Marketing Eli Lilly, FDA, anti-psychotic, boxed warning, lilly, olanzapine, skin condition
The US Food and Drug Administration (FDA) has issued a new warning to all drug labels for Eli Lilly’s antipsychotic …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
